Suppression of human prostate cancer cell growth by α1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis

Cancer Research

Volumn 60, Issue 16, 2000, Pages 4550-4555

  Kyprianou, N ^a   Benning, C M ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; PHENOXYBENZAMINE; TAMSULOSIN; TERAZOSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SMOOTH MUSCLE FIBER;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELLS, CULTURED; DOXAZOSIN; GROWTH INHIBITORS; HUMANS; MALE; MICE; MICE, SCID; MUSCLE, SMOOTH; NEOPLASM TRANSPLANTATION; PRAZOSIN; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ADRENERGIC, ALPHA-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034662630     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Cancer statistics
2. The role of androgens in prostatic cancer
3. Non-hormone chemotherapy for prostate cancer: Principles of treatment and application to the testing of new drugs
4. A controlled randomized trial of leuprolide with and without flutamide in prostatic cancer
5. Heterotrimeric G-proteins. Organizers of transmembrane signals
6. The α1 adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human α1 a subtype
7. α1 adrenergic stimulation and β2 adrenergic inhibition of DNA synthesis in vascular smooth muscle cells
8. Influence of the α1-adrenergic antagonist, doxazosin, on noradrenalin-induced modulation of cytoskeletal proteins in cultured hyperplastic prostatic stromal cells
9. Identification, quantification and localization of mRNA for three distinct α1 adrenoceptor subtypes in human prostate
10. α1-adrenoceptor subtypes in the human prostate
11. Prostatic adrenoceptors and uroselectivity
12. α-adrenergic blockers for the treatment of benign prostatic hyperplasia
13. Doxazosin in treatment of the lower urinary tract
14. Induction of prostate apoptosis by doxazosin
15. α1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patient with benign prostatic hyperplasia
16. Transforming growth factor-β1 transduced mouse prostate reconstitutions: Induction of prostate apoptosis by doxazosin
17. Endothelin-1 production and agonist activities in cultured prostate derived-cells: Implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia
18. Down-regulation of protein and mRNA expression for transforming growth factor-β (TGF-β) type I and type II receptors in human prostate cancer
19. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate hypertension: A double-blind, placebo-controlled, dose response multicenter study
20. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study
21. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia
22. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia
23. The hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia
24. Doxazosin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension
25. Pharmacokinetics of terazosin
26. Adverse effects of α1-adrenergic blocking drugs
27. Role of apoptosis in development of benign prostatic hyperplasia (BPH) and prostate cancer: Clinical significance in diagnosis and treatment
28. Doxazosin inhibits proliferation and migration of human vascular smooth-muscle cells independent of α1 adrenergic receptor antagonism
29. Long-term reduction of intimal hyperplasia by the selective α1-adrenergic antagonist doxazosin
30. Signal transduction via the MAP kinases: Proceed on your own